A phase II, randomized, double-blind, placebo-controlled study to:~Demonstrate the clinical efficacy of efalizumab in the treatment of subjects with psoriatic arthritis (PsA).~Evaluate the safety, tolerability and pharmacokinetics of efalizumab in the treatment of subjects with PsA
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)